China Pharma Holdings, Inc.CPHINYSE
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -39.00% | -47.25% | -17.05% | +10.90% | -31.26% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.00% | +0.00% | -10.48% | -31.44% | -18.58% |
| Weighted Average Shares Diluted Growth | +0.00% | +0.00% | -10.48% | -31.44% | -18.58% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -104.66% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +2.45% | -61.41% | -5.89% | +6.09% | -29.73% |
| Inventory Growth | -33.66% | -39.29% | -46.21% | -40.45% | -33.03% |
| Asset Growth | -12.29% | -9.60% | -12.19% | -3.47% | +18.71% |
| Book Value per Share Growth | +6.83% | +3.93% | -6.11% | +27.22% | +59.81% |
| Debt Growth | -25.64% | -22.51% | -15.82% | -15.56% | -11.04% |
| R&D Expense Growth | +91.40% | -99.63% | -5.93% | -87.25% | -53.98% |
| SG&A Expenses Growth | +5.93% | +8.91% | -0.39% | +166.63% | +4.84% |